MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
OrganiGram Holdings Retained Earnings 2011-2025 | OGI
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -145 M | -8.78 M | 759 K | -19.8 M | -8.87 M | -9.71 M | -833 K | -594 K | -219 K | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 759 K | -145 M | -21.4 M |
Quarterly Retained Earnings OrganiGram Holdings
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -276 M | - | - | - | -145 M | - | - | - | -8.78 M | - | - | - | 759 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 759 K | -276 M | -107 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.69 | -3.16 % | $ 182 M |  Canada |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 0.73 | -3.54 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 3.05 | -6.72 % | $ 1.63 B | Canada |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 5.17 | -4.22 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 12.03 | 5.34 % | $ 616 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.7 | 1.56 % | $ 1.23 B | USA |
 |
Evoke Pharma
EVOK
|
-123 M | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.87 | -5.71 % | $ 20.3 M | USA |
 |
Evolus
EOLS
|
-609 M | $ 7.18 | 1.92 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 45.82 | -2.64 % | $ 1.49 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.55 | -0.26 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 6.88 | -0.65 % | $ 2.51 B | Canada |
 |
Veru
VERU
|
-295 M | $ 2.44 | 0.83 % | $ 329 M | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.05 | 20.47 % | $ 42.9 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.39 | 13.52 % | $ 5.99 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.81 | -1.11 % | $ 237 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.32 | 6.4 % | $ 130 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 12.86 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | $ 0.12 | 0.17 % | $ 1.9 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.96 | -11.31 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.64 | -1.25 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 11.6 | -4.56 % | $ 7.17 B | Canada |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
-171 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 11.66 | 0.09 % | $ 14.1 B | USA |